"Organoplatinum Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Organic compounds which contain platinum as an integral part of the molecule.
Below are MeSH descriptors whose meaning is more general than "Organoplatinum Compounds".
Below are MeSH descriptors whose meaning is more specific than "Organoplatinum Compounds".
This graph shows the total number of publications written about "Organoplatinum Compounds" by people in this website by year, and whether "Organoplatinum Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Organoplatinum Compounds" by people in Profiles.
Staley SA, Tucker K, Newton M, Ertel M, Oldan J, Doherty I, West L, Zhang Y, Gehrig PA. Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy. Gynecol Oncol. 2020 03; 156(3):695-700.
Navez J, Remue C, Leonard D, Bachmann R, Kartheuser A, Hubert C, Coubeau L, Komuta M, Van den Eynde M, Zech F, Jabbour N. Surgical Treatment of Colorectal Cancer with Peritoneal and Liver Metastases Using Combined Liver and Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Report from a Single-Centre Experience. Ann Surg Oncol. 2016 12; 23(Suppl 5):666-673.
Chapuy CI, Sahai I, Sharma R, Zhu AX, Kozyreva ON. Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm. Oncologist. 2016 Apr; 21(4):514-20.
Dong Y, Zhao J, Wu CW, Zhang L, Liu X, Kang W, Leung WW, Zhang N, Chan FK, Sung JJ, Ng SS, Yu J. Tumor suppressor functions of miR-133a in colorectal cancer. Mol Cancer Res. 2013 Sep; 11(9):1051-60.
Rauh-Hain JA, Nitschmann CC, Worley MJ, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, del Carmen MG, Horowitz NS. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013 Apr; 129(1):63-8.
Moore N, Houghton J, Lyle S. Slow-cycling therapy-resistant cancer cells. Stem Cells Dev. 2012 Jul 01; 21(10):1822-30.
De Geest K, Blessing JA, Morris RT, Yamada SD, Monk BJ, Zweizig SL, Matei D, Muller CY, Richards WE. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol. 2010 Jan 01; 28(1):149-53.
Cerny J, Hassan A, Smith C, Piperdi B. Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen. Clin Colorectal Cancer. 2009 Jan; 8(1):55-8.
Lilenbaum R, Raez L, Tseng J, Seigel L, Davila E. Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer. J Thorac Oncol. 2008 May; 3(5):511-5.
Wanebo HJ, DiSiena M, Begossi G, Belliveau J, Gustafson E. Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum. Ann Surg Oncol. 2008 Apr; 15(4):1107-16.